ArticleInfection and immunity2009
Protection from pneumonic infection with burkholderia species by inhalational immunotherapy.
Article in Infection and immunity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 47 citations in OpenAlex.
- Glanders: Past, Present and Future of a Neglected Zoonosis as a Threat in Veterinary and Human Health.Veterinary medicine and science · 2026Review
- Evaluation of Immune Nanoparticles for Rapid and Non-Specific Activation of Antiviral and Antibacterial Immune Responses in Cattle, Swine, and Poultry.Animals : an open access journal from MDPI · 2023Article
- Nanoparticle ocular immunotherapy for herpesvirus surface eye infections evaluated in cat infection model.PloS one · 2023Article
- Article
- Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs.BMC veterinary research · 2019Article
- Activation of upper respiratory tract mucosal innate immune responses in cats by liposomal toll-like receptor ligand complexes delivered topically.Journal of veterinary internal medicine · 2019Article
- Evaluation of liposome toll-like receptor ligand complexes for non-specific mucosal immunoprotection from feline herpesvirus-1 infection.Journal of veterinary internal medicine · 2019Article
- Burkholderia pseudomallei ΔmSphere · 2019Article
- Article
- Outer Membrane Vesicle Vaccines from Biosafe Surrogates Prevent Acute Lethal Glanders in Mice.Vaccines · 2018Article
- An avirulent Burkholderia pseudomallei ∆purM strain with atypical type B LPS: expansion of the toolkit for biosafe studies of melioidosis.BMC microbiology · 2017Article
- Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Characterization of the murine macrophage response to infection with virulent and avirulent Burkholderia species.BMC microbiology · 2015Article
- Article
- Article
- Delineating the importance of serum opsonins and the bacterial capsule in affecting the uptake and killing of Burkholderia pseudomallei by murine neutrophils and macrophages.PLoS neglected tropical diseases · 2014Article
- Comparative Burkholderia pseudomallei natural history virulence studies using an aerosol murine model of infection.Scientific reports · 2014Article
- Immunotherapy for tularemia.Virulence · 2013Review
- Characterization of BcaA, a putative classical autotransporter protein in Burkholderia pseudomallei.Infection and immunity · 2013Article
- Post-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomallei.PLoS neglected tropical diseases · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Burkholderia mallei and B. pseudomallei are important human pathogens and cause the diseases glanders and melioidosis, respectively. Both organisms are highly infectious when inhaled and are inherently resistant to many antimicrobials, thus making it difficult to treat pneumonic Burkholderia infections. We investigated whether it was possible to achieve rapid protection against inhaled Burkholderia infection by using inhaled immunotherapy. For this purpose, cationic liposome DNA complexes (CLDC), which are potent activators of innate immunity, were used to elicit the activation of pulmonary innate immune responses. We found that mucosal CLDC administration before or shortly after bacterial challenge could generate complete or nearly complete protection from inhalational challenge with 100% lethal doses of B. mallei and B. pseudomallei. Protection was found to be dependent on the CLDC-mediated induction of gamma interferon responses in lung tissues and was partially dependent on the activation of NK cells. However, CLDC-mediated protection was not dependent on the induction of inducible nitric oxide synthase, as assessed by depletion studies. We concluded that the potent local activation of innate immune responses in the lung could be used to elicit rapid and nonspecific protection from aerosol exposure to both B. mallei and B. pseudomallei.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.